• Medientyp: E-Artikel
  • Titel: Left Atrial Appendage Closure in Atrial Fibrillation Patients with Cancer
  • Beteiligte: Zweiker, David; Bergler-Klein, Jutta; Fiedler, Lukas; Toth, Gabor G.; Achleitner, Reinhard; Schratter, Alexandra; Stix, Guenter; Gabriel, Harald; Binder, Ronald K.; Rammer, Martin; Pfeffer, Michael; Vock, Paul; Lileg, Brigitte; Steinwender, Clemens; Sihorsch, Kurt; Hintringer, Florian; Adukauskaite, Agne; Martinek, Martin; Sturmberger, Thomas; Ablasser, Klemens; Zirlik, Andreas; Scherr, Daniel
  • Erschienen: MDPI AG, 2024
  • Erschienen in: Journal of Clinical Medicine, 13 (2024) 21, Seite 6514
  • Sprache: Englisch
  • DOI: 10.3390/jcm13216514
  • ISSN: 2077-0383
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Background: There are limited data about left atrial appendage closure (LAAC) in patients with cancer. We therefore sought to compare the outcome after LAAC in patients with vs. without cancer in a multicentre registry. Methods: In this sub-analysis of the prospective Austrian LAAC Registry, we analysed consecutive patients undergoing LAAC to assess the relationship between baseline characteristics and outcome in patients with vs. without cancer. Inverse probability weighting was performed to adjust for differences in baseline characteristics. Results: A total of 486 consecutive patients from 9 centres with a median age of 75 years (IQR 70–79 years; 35.8% female) were included. Fifty-seven patients (11.7%) had a history of cancer. The median CHA2DS2-VASc and HAS-BLED scores were similar in both groups (median [IQR], 4 [4–6] vs. 5 [3–5], p = 0.415; 4 [3–4] vs. 3 [3–4], p = 0.428 in cancer vs. other patients). Cancer patients were significantly older, and anaemia and gastrointestinal bleeding were significantly more common. Major procedural complications occurred in 5.3% vs. 7.0% (p = 0.276) of patients. The cumulative five-year survival rates were 80.7% and 84.8% in cancer vs. other patients (adjusted hazard ratio for death 1.29 [95% CI 0.67–2.48], p = 0.443). There were also no differences in one-year survival (96.1% vs. 94.0%, p = 0.582) and five-year event-free survival (64.9% vs. 74.4%, p = 0.124). Conclusions: In daily clinical practice, LAAC has already been accepted as a treatment option in patients with cancer. This retrospective analysis shows that short-term and adjusted long-term complications are similar in patients with vs. without cancer undergoing LAAC.
  • Zugangsstatus: Freier Zugang